Continuation versus discontinuation of insulin secretagogues when initiating insulin in type 2 diabetes
Author:
Publisher
Wiley
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2010.01258.x/fullpdf
Reference6 articles.
1. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.;Nathan;Diabetes Care,2009
2. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.;Raskin;Diabetes Metab Res Rev,2008
3. Combined therapy with insulin plus oral agents: is there any advantage?;Riddle;Diabetes Care,2008
4. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: a multinational, randomized non-inferiority trial of basal insulin initiation in type 2 diabetes.;Swinnen;Diabetes Technol Ther,2009
5. Statistics notes: analysing controlled trials with baseline and follow up measurements.;Vickers;BMJ,2001
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Real-world incidence and risk factors for daytime and nocturnal non-severe hypoglycemia in adults with type 2 diabetes mellitus on insulin and/or secretagogues (InHypo-DM Study, Canada);Canadian Journal of Diabetes;2021-09
2. A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes;Diabetes/Metabolism Research and Reviews;2020-12
3. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials;Diabetes, Obesity and Metabolism;2020-01-27
4. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study;PLOS ONE;2019-02-13
5. Changes in metformin use and other antihyperglycemic therapies after insulin initiation in patients with type 2 diabetes;Diabetes Research and Clinical Practice;2018-05
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3